Emerging therapies in hematopoietic stem cell transplantation.
Despite improvements to hematopoietic stem cell transplantation over the past several decades, further advances are necessary to achieve: improved control of toxicities like graft-versus-host disease; enhanced immunologic reconstitution posttransplantation; and reduction in relapse risk via enhancement of graft-versus-tumor responses. Achieving these disparate hematopoietic stem cell transplantation goals will likely require the introduction of novel therapeutic agents to the current armamentarium. In this article, we outline preclinical and early-phase clinical data indicating the potential of proteasome-inhibitor therapy (bortezomib), hypomethylating agent therapy (azacytidine), and histone deacetylase-inhibitor therapy (vorinostat) to help improve hematopoietic stem cell transplantation outcomes.
University of Michigan, Ann Arbor, Michigan, USA.
Pavan
P
Reddy
Marcos
M
de Lima
John
J
Koreth
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology; D020350:Graft vs Tumor Effect / Q000187:drug effects*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*; D000077337:Vorinostat
D000970:Antineoplastic Agents; D001897:Boronic Acids; D006877:Hydroxamic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000077337:Vorinostat; D000069286:Bortezomib; D001374:Azacitidine